Benefit-risk Assessment of Cladribine Using Multi-criteria Decision Analysis (MCDA) for Patients With Relapsing-remitting Multiple Sclerosis

Vermersch P, Martinelli V, Pfleger C, Rieckmann P, Alonso-Magdalena L, Galazka A, Dangond F, Phillips L (2019)

Publication Type: Journal article

Publication year: 2019

Journal

Clinical Therapeutics Elsevier

Book Volume: 41

Pages Range: 249-260

Journal Issue: 2

DOI: 10.1016/j.clinthera.2018.12.015

Abstract

Purpose: We applied Multi-Criteria Decision Analysis (MCDA) methods in a structured benefit-risk assessment of cladribine and newer approved disease-modifying drugs (DMDs) for patients with relapsing-remitting multiple sclerosis (RRMS).

Additional Organisation(s)

Department of Neurology

Involved external institutions

LILLE 1 University - Science and Technology

France (FR) Skåne University Hospital / Skånes universitetssjukhus

Sweden (SE) EMD Serono

United States (USA) (US) The London School of Economics and Political Science

United Kingdom (GB) Aalborg University

Denmark (DK) Medical Park Loipl

Germany (DE) Merck & Co., Inc. / Merck Sharp & Dohme Corp (MSD)

United States (USA) (US) Ospedale San Raffaele (früher: Centro San Raffaele del Monte Tabor Foundation)

Italy (IT)

How to cite

APA:

Vermersch, P., Martinelli, V., Pfleger, C., Rieckmann, P., Alonso-Magdalena, L., Galazka, A.,... Phillips, L. (2019). Benefit-risk Assessment of Cladribine Using Multi-criteria Decision Analysis (MCDA) for Patients With Relapsing-remitting Multiple Sclerosis. Clinical Therapeutics, 41(2), 249-260. https://dx.doi.org/10.1016/j.clinthera.2018.12.015

MLA:

Vermersch, Patrick, et al. "Benefit-risk Assessment of Cladribine Using Multi-criteria Decision Analysis (MCDA) for Patients With Relapsing-remitting Multiple Sclerosis." Clinical Therapeutics 41.2 (2019): 249-260.

BibTeX: Download